Investigational drug · Phase 2
JMT601
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Membranous Nephropathy.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "JMT601"
First trial start
2025
Jun 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JMT601", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Membranous Nephropathy
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "JMT601" as an intervention, largest first.
Shanghai JMT-Bio Inc.Industry
NCT06725524 · 186 participants (planned) · Start Oct 12, 2021 · Primary completion Dec 31, 2025
Drug: JMT601 · For: B-cell Non Hodgkin Lymphoma
Sites: Shanghai, China
- A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous NephropathyPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT07029139 · 156 participants (planned) · Start Jun 30, 2025 · Primary completion Apr 1, 2027
Drug: JMT601 Injection; Rituximab and 1 more · For: Primary Membranous Nephropathy
Conjupro Biotherapeutics, Inc.Industry
NCT04853329 · 7 participants · Start Dec 13, 2021 · Primary completion Jan 31, 2023
Drug: CPO107 · For: CD20 Positive Non Hodgkin Lymphoma
Sites: Charlotte, North Carolina
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Primary Membranous Nephropathy
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- MIL62Phase 34 trials
Beijing Mabworks Biotech Co., Ltd. · Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy
- B007Phase 33 trials
Shanghai Jiaolian Drug Research and Development Co., Ltd · Pemphigus, Primary Membranous Nephropathy, Generalized Myasthenia Gravis
- CyclosporinPhase 32 trials
Shanghai JMT-Bio Inc. · Primary Membranous Nephropathy
- ZuberitamabPhase 32 trials
BioRay Pharmaceutical Co., Ltd. · Primary Membranous Nephropathy
- SHR-2173Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy
- BudoprutugTNT119Phase 23 trials
Climb Bio, Inc. · Primary Membranous Nephropathy, Systemic Lupus Erthematosus, Immune Thrombocytopenia (ITP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.